Cartesian Therapeutics (RNAC) Accounts Payables (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Accounts Payables data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 23.8% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 23.8% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, up 347.22% from the prior year.
• Accounts Payables for Q1 2026 stood at $1.6 million, up from $1.3 million in the prior quarter.
• Over the last five years, Accounts Payables for RNAC reached as high as $3.2 million in Q4 2023 and fell as low as $214000.0 in Q3 2022.
• Historically, Accounts Payables has averaged $1.2 million across 5 years, with a median of $693000.0 in 2022.
• On a YoY basis, Accounts Payables climbed as much as 971.91% in 2024 and fell as far as 90.86% in 2024.
• Year by year, Accounts Payables stood at $316000.0 in 2022, then soared by 896.84% to $3.2 million in 2023, then plunged by 90.86% to $288000.0 in 2024, then soared by 347.22% to $1.3 million in 2025, then grew by 24.07% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $1.6 million in Q1 2026, $1.3 million in Q4 2025, and $2.2 million in Q3 2025.